Home » Posts tagged with » Biogen
Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for the treatment of depression and movement disorders. Under the terms of the deal, the two US pharma companies will jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), […]

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ophthalmology biosimilar referencing Genentech’s Lucentis (ranibizumab). Ranibizumab is an anti vascular endothelial growth factor (VEGF) therapy for retinal vascular disorders, which are a major cause of blindness in the US. […]

Continue reading …
Mylan gets favorable court decision in Biogen’s Tecfidera patent case

Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen’s Tecfidera patent U.S. Patent No. 8,399,514 for lack of written description. According to the company, the 8,399,514 patent claimed methods for the treatment of multiple sclerosis (MS) with a dose of 480 mg/day of dimethyl […]

Continue reading …
Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD

Eisai and Biogen have decided to stop the MISSION AD1 and AD2 phase 3 clinical studies on elenbecestat in early Alzheimer’s disease (AD) owing to safety concerns, as per the latest clinical trial news. The decision has been driven by the findings of a safety review undertaken by the Data Safety Monitoring Board (DSMB), which […]

Continue reading …
Biogen to acquire UK gene therapy company Nightstar Therapeutics for $800m

Biogen acquisition of Nightstar Therapeutics : US biotech company Biogen has signed a deal of $800 million to acquire Nightstar Therapeutics, a British clinical-stage gene therapy company, as per the latest pharma acquisition news. Nightstar Therapeutics primarily focuses on the developing adeno-associated virus (AAV) treatments for inherited retinal disorders. Biogen acquisition of Nightstar Therapeutics According […]

Continue reading …